Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $733,670.88 in Stock

Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno sold 51,234 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $14.32, for a total value of $733,670.88. Following the completion of the transaction, the chief executive officer now directly owns 217,351 shares of the company’s stock, valued at approximately $3,112,466.32. This trade represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Paul Bolno also recently made the following trade(s):

• On Wednesday, October 16th, Paul Bolno sold 90,474 shares of Wave Life Sciences stock. The stock was sold at an average price of $15.00, for a total transaction of $1,357,110.00.
• On Wednesday, August 21st, Paul Bolno sold 48,366 shares of Wave Life Sciences stock. The shares were sold at an average price of $5.78, for a total value of $279,555.48.

Wave Life Sciences Trading Down 8.9 %

Shares of NASDAQ WVE opened at $13.67 on Monday. The stock has a fifty day moving average price of $10.76 and a 200 day moving average price of $7.54. Wave Life Sciences Ltd. has a 12-month low of $3.50 and a 12-month high of $16.74. The company has a market cap of $2.08 billion, a P/E ratio of -12.32 and a beta of -1.20.

Institutional Investors Weigh In On Wave Life Sciences

A number of large investors have recently modified their holdings of WVE. Privium Fund Management B.V. acquired a new position in Wave Life Sciences during the 3rd quarter worth approximately $400,000. Moody Aldrich Partners LLC lifted its holdings in Wave Life Sciences by 69.0% in the 3rd quarter. Moody Aldrich Partners LLC now owns 303,062 shares of the company’s stock worth $2,485,000 after buying an additional 123,703 shares in the last quarter. SG Americas Securities LLC purchased a new position in Wave Life Sciences in the 2nd quarter valued at about $668,000. Vanguard Group Inc. grew its stake in shares of Wave Life Sciences by 39.7% during the first quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock valued at $11,316,000 after acquiring an additional 521,665 shares in the last quarter. Finally, Driehaus Capital Management LLC increased its position in shares of Wave Life Sciences by 62.2% during the second quarter. Driehaus Capital Management LLC now owns 908,096 shares of the company’s stock worth $4,531,000 after acquiring an additional 348,300 shares during the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on WVE shares. JPMorgan Chase & Co. lifted their price target on Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, October 17th. Truist Financial upped their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Royal Bank of Canada lifted their price target on shares of Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a report on Monday, October 21st. StockNews.com lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, November 13th. Finally, B. Riley boosted their price target on Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Wave Life Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $21.89.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.